← Eichor
Study identifier: NCT06580002 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Condition: Breast Cancer · Sarcoma · Gastric Cancer  ·  Sponsor: University of California, Irvine

PhasePhase 2
Planned participants75
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.

This description comes directly from the study's public registry record.

Talk to the study team

Chao Family Comprehensive Cancer Center University of California, Irvine  ·  1-877-827-8839  ·  ucstudy@uci.edu

University of California Irvine Medical

Always discuss trial participation with your own doctor first.

Locations (1)

Chao Family Comprehensive Cancer Center, University of California IrvineOrange, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06580002